Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT06533059

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

Led by Alterome Therapeutics, Inc. · Updated on 2026-03-09

110

Participants Needed

51

Research Sites

174 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.

CONDITIONS

Official Title

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed solid tumor with AKT1 E17K mutation using certified molecular testing
  • Unresectable or metastatic disease
  • Progressed on, intolerant to, or declined prior standard therapies suitable for tumor type and stage
  • Measurable or evaluable disease by RECIST v1.1
  • ECOG performance status of 0 or 1
  • Adequate organ function
Not Eligible

You will not qualify if you...

  • Previous treatment with PI3K or mTOR inhibitors
  • Known tumor mutations in KRAS, NRAS, HRAS, or BRAF
  • Conditions preventing swallowing or absorption of oral medications

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 51 locations

1

Research Site

La Jolla, California, United States, 92093

Actively Recruiting

2

Research Site

Los Angeles, California, United States, 90095

Actively Recruiting

3

Research Site

Denver, Colorado, United States, 80218

Actively Recruiting

4

Research Site

Sarasota, Florida, United States, 34232

Actively Recruiting

5

Research Site

Atlanta, Georgia, United States, 30322

Actively Recruiting

6

Research Site

Boston, Massachusetts, United States, 02114

Actively Recruiting

7

Research Site

Boston, Massachusetts, United States, 02215

Actively Recruiting

8

Research Site

St Louis, Missouri, United States, 63110

Actively Recruiting

9

Research Site

Mineola, New York, United States, 11501

Actively Recruiting

10

Research Site

New York, New York, United States, 10016

Actively Recruiting

11

Research Site

Maumee, Ohio, United States, 43637

Actively Recruiting

12

Research Site

Nashville, Tennessee, United States, 37203

Actively Recruiting

13

Research Site

Dallas, Texas, United States, 75230

Withdrawn

14

Research Site

Houston, Texas, United States, 77030

Actively Recruiting

15

Research Site #2

San Antonio, Texas, United States, 78229

Actively Recruiting

16

Research Site

San Antonio, Texas, United States, 78229

Actively Recruiting

17

Research Site

Fairfax, Virginia, United States, 22031

Actively Recruiting

18

Research Site

Madison, Wisconsin, United States, 53792

Actively Recruiting

19

Research Site

Blacktown, New South Wales, Australia, 2148

Actively Recruiting

20

Research Site

Randwick, New South Wales, Australia, 2031

Actively Recruiting

21

Research Site

South Brisbane, Queensland, Australia, 4101

Actively Recruiting

22

Research Site

Malvern, Victoria, Australia, 3144

Actively Recruiting

23

Research Site

Nedlands, Western Australia, Australia, 6009

Actively Recruiting

24

Research Site

Caen, France, 14000

Actively Recruiting

25

Research Site

Dijon, France, 21000

Actively Recruiting

26

Research Site

Saint-Herblain, France, 44805

Actively Recruiting

27

Research Site

Villejuif, France, 94800

Actively Recruiting

28

Research Site

Kyoto, Japan, 606-8507

Actively Recruiting

29

Research Site

Matsuyama, Japan, 791-0280

Actively Recruiting

30

Research Site

Shizuoka, Japan, 411-8777

Actively Recruiting

31

Research Site

Tokyo, Japan, 135-8550

Actively Recruiting

32

Research Site

Seoul, South Korea, 03722

Actively Recruiting

33

Research Site

Seoul, South Korea, 05505

Actively Recruiting

34

Research Site

Seoul, South Korea, 06351

Actively Recruiting

35

Research Site

Seoul, South Korea, 06591

Actively Recruiting

36

Research Site

Seoul, South Korea, 13620

Actively Recruiting

37

Research Site

Barcelona, Spain, 08023

Actively Recruiting

38

Research Site

Barcelona, Spain, 08035

Actively Recruiting

39

Research Site

Barcelona, Spain, 08908

Actively Recruiting

40

Research Site

Madrid, Spain, 28023

Actively Recruiting

41

Research Site

Madrid, Spain, 28040

Actively Recruiting

42

Research Site

Valencia, Spain, 46010

Actively Recruiting

43

Research Site

Changhua, Taiwan, 500

Actively Recruiting

44

Research Site

Taipei, Taiwan, 100

Actively Recruiting

45

Research Site

Taipei, Taiwan, 10449

Actively Recruiting

46

Research Site

London, United Kingdom, SW3 6JJ

Actively Recruiting

47

Research Site

London, United Kingdom, W1G 6AD

Actively Recruiting

48

Research Site

London, United Kingdom, W1T 7HA

Actively Recruiting

49

Research Site

Manchester, United Kingdom, M10 4BX

Actively Recruiting

50

Research Site

Newcastle upon Tyne, United Kingdom, NE7 7DN

Actively Recruiting

51

Research Site

Sutton, United Kingdom, SM2 5PT

Actively Recruiting

Loading map...

Research Team

A

Alterome Clinical Trial Contact Center

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | DecenTrialz